19-norandrostenedione

Identification

Name

19-norandrostenedione

Accession Number

DB01434

Type

Small Molecule

Groups

Experimental, Illicit

Description

19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.

In the body 19-norandrostenedione is rapidly metabolized into nandrolone, also known as nortestosterone.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB01434 (19-norandrostenedione)

×

Close

Synonyms

• 4-estrene-3,17-dione
• delta4-Estrene-3,17-dione
• NOR

External IDs

NSC-12164

Product Ingredients

Not Available

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International/Other Brands

19-N-Andro / Bolandione / Proven Pure 19-Norandrostenedione

Brand mixtures

Not Available

Categories

• 17-Ketosteroids
• Adrenal Cortex Hormones
• Androstanes
• Androstenes
• Gonadal Hormones
• Gonadal Steroid Hormones
• Hormones
• Hormones, Hormone Substitutes, and Hormone Antagonists
• Ketosteroids
• Steroids
• Testosterone Congeners

UNII

U90987PVU5

CAS number

734-32-7

Weight

Average: 272.382
Monoisotopic: 272.177630012

Chemical Formula

C₁₈H₂₄O₂

InChI Key

JRIZOGLBRPZBLQ-QXUSFIETSA-N

InChI

InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-16H,2-9H2,1H3/t13-,14+,15+,16-,18-/m0/s1

IUPAC Name

(1S,2R,10R,11S,15S)-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-ene-5,14-dione

SMILES

[H][[email protected]@]12CCC(=O)[[email protected]@]1(C)CC[[email protected]]1([H])[[email protected]@]3([H])CCC(=O)C=C3CC[[email protected]@]21[H]

Pharmacology

Indication

The claim that supplemental 19-norandrostenedione has anabolic effects is unsubstantiated.

Structured Indications

Not Available

Pharmacodynamics

Not Available

Mechanism of action

19-Norandrostenedione may be metabolized to 19-nortestosterone in both men and women. 19-Norandrostenedione, also known as nandrolone, is the basic substance of some very popular injectable anabolic steroids, however 19-norandrostenedione is not metabolized to testosterone. Whether or not increases in 19-nortestosterone levels would be sustained long enough by taking 19-norandrostenedione to show an increase in nitrogen retention and muscle strength and mass is unknown.

19-Norandrostenedione has also been shown to bind to androgen receptors with high selectivity. Transactivation of androgen receptor dependent reporter gene expression was 10 times lower than that produced by dihydrotestosterone. [1]

Absorption

Absorption appears variable, but some absorption does occur.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Specific metabolites of 19-nor-5-androstene-3, 17-dione are 19-nordehydroandrosterone and 19-nordehydroepiandrosterone.

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

• Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
1,10-Phenanthroline	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with 1,10-Phenanthroline.	Experimental
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with 19-norandrostenedione.	Approved
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with 19-norandrostenedione.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with 19-norandrostenedione.	Approved
Aldesleukin	19-norandrostenedione may decrease the antineoplastic activities of Aldesleukin.	Approved
Aluminum hydroxide	The bioavailability of 19-norandrostenedione can be decreased when combined with Aluminum hydroxide.	Approved
Ambenonium	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ambenonium.	Approved
Aminosalicylic Acid	The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 19-norandrostenedione.	Approved
Amiodarone	The serum concentration of 19-norandrostenedione can be increased when it is combined with Amiodarone.	Approved, Investigational
Amphotericin B	19-norandrostenedione may increase the hypokalemic activities of Amphotericin B.	Approved, Investigational
Andrographolide	The risk or severity of adverse effects can be increased when HMPL-004 is combined with 19-norandrostenedione.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Anisodamine is combined with 19-norandrostenedione.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with 19-norandrostenedione.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Acetovanillone is combined with 19-norandrostenedione.	Investigational
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with 19-norandrostenedione.	Approved, Investigational
Aprepitant	The serum concentration of 19-norandrostenedione can be increased when it is combined with Aprepitant.	Approved, Investigational
Atazanavir	The serum concentration of 19-norandrostenedione can be increased when it is combined with Atazanavir.	Approved, Investigational
Atracurium besylate	Atracurium besylate may increase the adverse neuromuscular activities of 19-norandrostenedione.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Azapropazone is combined with 19-norandrostenedione.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with 19-norandrostenedione.	Approved
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with 19-norandrostenedione.	Approved, Investigational
Bazedoxifene	The serum concentration of 19-norandrostenedione can be increased when it is combined with Bazedoxifene.	Approved, Investigational
Bendroflumethiazide	19-norandrostenedione may increase the hypokalemic activities of Bendroflumethiazide.	Approved
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with 19-norandrostenedione.	Withdrawn
Benzoic Acid	The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with 19-norandrostenedione.	Approved
Betulinic Acid	The risk or severity of adverse effects can be increased when Betulinic Acid is combined with 19-norandrostenedione.	Investigational
Bismuth Subcitrate	The bioavailability of 19-norandrostenedione can be decreased when combined with Bismuth Subcitrate.	Approved
Boceprevir	The serum concentration of 19-norandrostenedione can be increased when it is combined with Boceprevir.	Withdrawn
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with 19-norandrostenedione.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Bucillamine is combined with 19-norandrostenedione.	Investigational
Bumetanide	19-norandrostenedione may increase the hypokalemic activities of Bumetanide.	Approved
Calcitriol	The therapeutic efficacy of Calcitriol can be decreased when used in combination with 19-norandrostenedione.	Approved, Nutraceutical
Calcium Carbonate	The bioavailability of 19-norandrostenedione can be decreased when combined with Calcium carbonate.	Approved
Carbamazepine	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with 19-norandrostenedione.	Approved, Vet Approved, Withdrawn
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with 19-norandrostenedione.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Celecoxib is combined with 19-norandrostenedione.	Approved, Investigational
Ceritinib	19-norandrostenedione may increase the hyperglycemic activities of Ceritinib.	Approved
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with 19-norandrostenedione.	Approved, Vet Approved
Chlorothiazide	19-norandrostenedione may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Chlorotrianisene	The serum concentration of 19-norandrostenedione can be increased when it is combined with Chlorotrianisene.	Withdrawn
Chlorthalidone	19-norandrostenedione may increase the hypokalemic activities of Chlorthalidone.	Approved
Cholestyramine	Cholestyramine can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with 19-norandrostenedione.	Approved
Cinoxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Cinoxacin.	Approved, Withdrawn
Ciprofloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ciprofloxacin.	Approved, Investigational
Clarithromycin	The serum concentration of 19-norandrostenedione can be increased when it is combined with Clarithromycin.	Approved
Clonixin	The risk or severity of adverse effects can be increased when Clonixin is combined with 19-norandrostenedione.	Approved
Cobicistat	The serum concentration of 19-norandrostenedione can be increased when it is combined with Cobicistat.	Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Conjugated estrogens	The serum concentration of 19-norandrostenedione can be increased when it is combined with Conjugated Equine Estrogens.	Approved
Corticorelin ovine triflutate	The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with 19-norandrostenedione.	Approved
Coumaphos	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Coumaphos.	Vet Approved
Curcumin	The risk or severity of adverse effects can be increased when Curcumin is combined with 19-norandrostenedione.	Investigational
D-Limonene	The risk or severity of adverse effects can be increased when D-Limonene is combined with 19-norandrostenedione.	Investigational
Darunavir	The serum concentration of 19-norandrostenedione can be increased when it is combined with Darunavir.	Approved
Decamethonium	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Decamethonium.	Approved
Deferasirox	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Deferasirox.	Approved, Investigational
Demecarium	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Demecarium.	Approved
dersalazine	The risk or severity of adverse effects can be increased when dersalazine is combined with 19-norandrostenedione.	Investigational
Dichlorvos	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Dichlorvos.	Vet Approved
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with 19-norandrostenedione.	Approved, Vet Approved
Dienestrol	The serum concentration of 19-norandrostenedione can be increased when it is combined with Dienestrol.	Approved
Diethylstilbestrol	The serum concentration of 19-norandrostenedione can be increased when it is combined with Diethylstilbestrol.	Approved
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with 19-norandrostenedione.	Approved
Dihydrotestosterone	19-norandrostenedione may increase the fluid retaining activities of Dihydrotestosterone.	Illicit
Donepezil	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Donepezil.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Droxicam is combined with 19-norandrostenedione.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Duvelisib is combined with 19-norandrostenedione.	Investigational
E-6201	The risk or severity of adverse effects can be increased when E6201 is combined with 19-norandrostenedione.	Investigational
Ebselen	The risk or severity of adverse effects can be increased when Ebselen is combined with 19-norandrostenedione.	Investigational
Echothiophate	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Echothiophate.	Approved
Edrophonium	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Edrophonium.	Approved
Enoxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Enoxacin.	Approved
Enzalutamide	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Enzalutamide.	Approved
Epirizole	The risk or severity of adverse effects can be increased when Epirizole is combined with 19-norandrostenedione.	Approved
Equol	The serum concentration of 19-norandrostenedione can be increased when it is combined with S Equol.	Investigational
Estradiol	The serum concentration of 19-norandrostenedione can be increased when it is combined with Estradiol.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of 19-norandrostenedione can be increased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of 19-norandrostenedione can be increased when it is combined with Estrone.	Approved
Etacrynic acid	19-norandrostenedione may increase the hypokalemic activities of Etacrynic acid.	Approved
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with 19-norandrostenedione.	Approved, Investigational
Ethinyl Estradiol	The serum concentration of 19-norandrostenedione can be increased when it is combined with Ethinyl Estradiol.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Etodolac is combined with 19-norandrostenedione.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Etofenamate is combined with 19-norandrostenedione.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Etoricoxib is combined with 19-norandrostenedione.	Approved, Investigational
Evening primrose oil	The risk or severity of adverse effects can be increased when Evening primrose oil is combined with 19-norandrostenedione.	Approved
exisulind	The risk or severity of adverse effects can be increased when exisulind is combined with 19-norandrostenedione.	Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Fenbufen is combined with 19-norandrostenedione.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with 19-norandrostenedione.	Approved
Fenthion	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fenthion.	Vet Approved
Fleroxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with 19-norandrostenedione.	Approved, Withdrawn
Flumequine	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Flumequine.	Withdrawn
Flunixin	The risk or severity of adverse effects can be increased when Flunixin is combined with 19-norandrostenedione.	Vet Approved
Fluoxymesterone	19-norandrostenedione may increase the fluid retaining activities of Fluoxymesterone.	Approved, Illicit
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with 19-norandrostenedione.	Approved, Investigational
Fosaprepitant	The serum concentration of 19-norandrostenedione can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Fosphenytoin.	Approved
Furosemide	19-norandrostenedione may increase the hypokalemic activities of Furosemide.	Approved, Vet Approved
G17DT	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with G17DT.	Investigational
Galantamine	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Galantamine.	Approved
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gallamine Triethiodide.	Approved
Garenoxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Garenoxacin.	Investigational
Gatifloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gatifloxacin.	Approved, Investigational
Gemifloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gemifloxacin.	Approved, Investigational
Genistein	The serum concentration of 19-norandrostenedione can be increased when it is combined with Genistein.	Investigational
GI-5005	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with GI-5005.	Investigational
Ginkgo biloba	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ginkgo biloba.	Approved, Nutraceutical
Glycerol Phenylbutyrate	The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with 19-norandrostenedione.	Approved
Grepafloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Grepafloxacin.	Withdrawn
Hexestrol	The serum concentration of 19-norandrostenedione can be increased when it is combined with Hexestrol.	Withdrawn
Higenamine	The risk or severity of adverse effects can be increased when Higenamine is combined with 19-norandrostenedione.	Investigational
Huperzine A	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Huperzine A.	Investigational
Hyaluronidase	The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 19-norandrostenedione.	Approved, Investigational
Hydrochlorothiazide	19-norandrostenedione may increase the hypokalemic activities of Hydrochlorothiazide.	Approved, Vet Approved
Hydroflumethiazide	19-norandrostenedione may increase the hypokalemic activities of Hydroflumethiazide.	Approved
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with 19-norandrostenedione.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Ibuproxam is combined with 19-norandrostenedione.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with 19-norandrostenedione.	Approved
Idelalisib	The serum concentration of 19-norandrostenedione can be increased when it is combined with Idelalisib.	Approved
Indacaterol	Indacaterol may increase the hypokalemic activities of 19-norandrostenedione.	Approved
Indapamide	19-norandrostenedione may increase the hypokalemic activities of Indapamide.	Approved
Indinavir	The serum concentration of 19-norandrostenedione can be increased when it is combined with Indinavir.	Approved
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with 19-norandrostenedione.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Indoprofen is combined with 19-norandrostenedione.	Withdrawn
INGN 201	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 225.	Investigational
Isoflurophate	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Isoflurophate.	Approved, Withdrawn
Isoniazid	The serum concentration of Isoniazid can be decreased when it is combined with 19-norandrostenedione.	Approved
Isoxicam	The risk or severity of adverse effects can be increased when Isoxicam is combined with 19-norandrostenedione.	Withdrawn
Itraconazole	The serum concentration of 19-norandrostenedione can be increased when it is combined with Itraconazole.	Approved, Investigational
Kebuzone	The risk or severity of adverse effects can be increased when Kebuzone is combined with 19-norandrostenedione.	Experimental
Ketoconazole	The serum concentration of 19-norandrostenedione can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with 19-norandrostenedione.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with 19-norandrostenedione.	Approved
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with 19-norandrostenedione.	Approved, Investigational
Levofloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Levofloxacin.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Lisofylline is combined with 19-norandrostenedione.	Investigational
Lomefloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Lomefloxacin.	Approved
Lopinavir	The serum concentration of 19-norandrostenedione can be increased when it is combined with Lopinavir.	Approved
Lornoxicam	The risk or severity of adverse effects can be increased when Lornoxicam is combined with 19-norandrostenedione.	Approved
Loxoprofen	The risk or severity of adverse effects can be increased when Loxoprofen is combined with 19-norandrostenedione.	Approved
Lumacaftor	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Lumiracoxib is combined with 19-norandrostenedione.	Approved, Investigational
Magaldrate	The bioavailability of 19-norandrostenedione can be decreased when combined with Magaldrate.	Withdrawn
Magnesium carbonate	The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium carbonate.	Approved
Magnesium Hydroxide	The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium hydroxide.	Approved
Magnesium oxide	The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium oxide.	Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 19-norandrostenedione.	Approved
Magnesium Trisilicate	The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium Trisilicate.	Approved
Malathion	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Malathion.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with 19-norandrostenedione.	Approved
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 19-norandrostenedione.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with 19-norandrostenedione.	Approved
Mefloquine	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Mefloquine.	Approved
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with 19-norandrostenedione.	Approved, Vet Approved
Memantine	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Memantine.	Approved, Investigational
Mesalazine	The risk or severity of adverse effects can be increased when Mesalazine is combined with 19-norandrostenedione.	Approved
Mestranol	The serum concentration of 19-norandrostenedione can be increased when it is combined with Mestranol.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with 19-norandrostenedione.	Withdrawn
Methallenestril	The serum concentration of 19-norandrostenedione can be increased when it is combined with Methallenestril.	Experimental
Methanesulfonyl Fluoride	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Methanesulfonyl Fluoride.	Investigational
Methyclothiazide	19-norandrostenedione may increase the hypokalemic activities of Methyclothiazide.	Approved
Methyltestosterone	19-norandrostenedione may increase the fluid retaining activities of Methyltestosterone.	Approved
Metolazone	19-norandrostenedione may increase the hypokalemic activities of Metolazone.	Approved
Mifepristone	The therapeutic efficacy of 19-norandrostenedione can be decreased when used in combination with Mifepristone.	Approved, Investigational
Minaprine	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Minaprine.	Approved
Mitotane	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Mitotane.	Approved
Mivacurium	Mivacurium may increase the adverse neuromuscular activities of 19-norandrostenedione.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Mizoribine is combined with 19-norandrostenedione.	Investigational
Moxifloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 19-norandrostenedione.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 19-norandrostenedione.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Nabumetone is combined with 19-norandrostenedione.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Nafamostat is combined with 19-norandrostenedione.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with 19-norandrostenedione.	Approved
Nalidixic Acid	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nalidixic Acid.	Approved
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with 19-norandrostenedione.	Approved, Vet Approved
Nefazodone	The serum concentration of 19-norandrostenedione can be increased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of 19-norandrostenedione can be increased when it is combined with Nelfinavir.	Approved
Nemonoxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nemonoxacin.	Investigational
Neostigmine	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Neostigmine.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with 19-norandrostenedione.	Approved
Nevirapine	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Nevirapine.	Approved
Nicorandil	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nicorandil.	Approved
Niflumic Acid	The risk or severity of adverse effects can be increased when Niflumic Acid is combined with 19-norandrostenedione.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with 19-norandrostenedione.	Approved, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Nitroaspirin is combined with 19-norandrostenedione.	Investigational
Norfloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Norfloxacin.	Approved
Ofloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ofloxacin.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with 19-norandrostenedione.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with 19-norandrostenedione.	Approved
Orgotein	The risk or severity of adverse effects can be increased when Orgotein is combined with 19-norandrostenedione.	Vet Approved
Oxandrolone	19-norandrostenedione may increase the fluid retaining activities of Oxandrolone.	Approved, Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with 19-norandrostenedione.	Approved
Oxymetholone	19-norandrostenedione may increase the fluid retaining activities of Oxymetholone.	Approved, Illicit
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 19-norandrostenedione.	Withdrawn
Parecoxib	The risk or severity of adverse effects can be increased when Parecoxib is combined with 19-norandrostenedione.	Approved
Pazufloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pazufloxacin.	Investigational
Pefloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pefloxacin.	Approved
Pentobarbital	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Pentobarbital.	Approved, Vet Approved
Phenobarbital	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenobarbital.	Approved
Phenylacetic acid	The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with 19-norandrostenedione.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with 19-norandrostenedione.	Approved, Vet Approved
Phenylbutyric acid	The therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with 19-norandrostenedione.	Approved, Investigational
Phenytoin	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Physostigmine	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Physostigmine.	Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with 19-norandrostenedione.	Approved, Investigational
Piretanide	19-norandrostenedione may increase the hypokalemic activities of Piretanide.	Experimental
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with 19-norandrostenedione.	Investigational
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with 19-norandrostenedione.	Approved, Investigational
Polyestradiol phosphate	The serum concentration of 19-norandrostenedione can be increased when it is combined with Polyestradiol phosphate.	Approved
Polythiazide	19-norandrostenedione may increase the hypokalemic activities of Polythiazide.	Approved
Posaconazole	The serum concentration of 19-norandrostenedione can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Primidone	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Primidone.	Approved, Vet Approved
Promestriene	The serum concentration of 19-norandrostenedione can be increased when it is combined with Promestriene.	Investigational
Propacetamol	The risk or severity of adverse effects can be increased when Propacetamol is combined with 19-norandrostenedione.	Approved
Prulifloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with 19-norandrostenedione.	Investigational
Pyridostigmine	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pyridostigmine.	Approved
Quinestrol	The serum concentration of 19-norandrostenedione can be increased when it is combined with Quinestrol.	Approved
Quinethazone	19-norandrostenedione may increase the hypokalemic activities of Quinethazone.	Approved
Rabies virus inactivated antigen, A	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rabies vaccine.	Approved
Rapacuronium	Rapacuronium may increase the adverse neuromuscular activities of 19-norandrostenedione.	Withdrawn
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with 19-norandrostenedione.	Experimental, Investigational
Rifabutin	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifabutin.	Approved
Rifampicin	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifapentine.	Approved
Rindopepimut	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with CDX-110.	Investigational
Ritonavir	The serum concentration of 19-norandrostenedione can be increased when it is combined with Ritonavir.	Approved, Investigational
Rivastigmine	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rivastigmine.	Approved, Investigational
Rofecoxib	The risk or severity of adverse effects can be increased when Rofecoxib is combined with 19-norandrostenedione.	Investigational, Withdrawn
Rosoxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rosoxacin.	Approved
Salicylamide	The risk or severity of adverse effects can be increased when Salicylamide is combined with 19-norandrostenedione.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with 19-norandrostenedione.	Approved, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with 19-norandrostenedione.	Approved
Saquinavir	The serum concentration of 19-norandrostenedione can be increased when it is combined with Saquinavir.	Approved, Investigational
Secoisolariciresinol	The serum concentration of 19-norandrostenedione can be increased when it is combined with Secoisolariciresinol.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Seratrodast is combined with 19-norandrostenedione.	Approved
Sparfloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Sparfloxacin.	Approved
SRP 299	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with SRP 299.	Investigational
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with 19-norandrostenedione.	Investigational
St. John's Wort	The serum concentration of 19-norandrostenedione can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stanozolol	19-norandrostenedione may increase the fluid retaining activities of Stanozolol.	Approved, Vet Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with 19-norandrostenedione.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with 19-norandrostenedione.	Approved
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with 19-norandrostenedione.	Approved, Withdrawn
Synthetic Conjugated Estrogens, A	The serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, A.	Approved
Synthetic Conjugated Estrogens, B	The serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, B.	Approved
Tacrine	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tacrine.	Withdrawn
Telaprevir	The serum concentration of Telaprevir can be decreased when it is combined with 19-norandrostenedione.	Withdrawn
Telithromycin	The serum concentration of 19-norandrostenedione can be increased when it is combined with Telithromycin.	Approved
Temafloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Temafloxacin.	Withdrawn
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with 19-norandrostenedione.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Tepoxalin is combined with 19-norandrostenedione.	Vet Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with 19-norandrostenedione.	Approved
Testosterone	19-norandrostenedione may increase the fluid retaining activities of Testosterone.	Approved, Investigational
TG4010	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with TG4010.	Investigational
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 19-norandrostenedione.	Approved
Tibolone	The serum concentration of 19-norandrostenedione can be increased when it is combined with Tibolone.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Tinoridine is combined with 19-norandrostenedione.	Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 19-norandrostenedione.	Approved
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with 19-norandrostenedione.	Approved
Torasemide	19-norandrostenedione may increase the hypokalemic activities of Torasemide.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Tranilast is combined with 19-norandrostenedione.	Approved, Investigational
Trichlorfon	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Trichlorfon.	Vet Approved
Trichlormethiazide	19-norandrostenedione may increase the hypokalemic activities of Trichlormethiazide.	Approved, Vet Approved
Trovafloxacin	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Trovafloxacin.	Approved, Withdrawn
Tubocurarine	The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tubocurarine.	Approved
Valdecoxib	The risk or severity of adverse effects can be increased when Valdecoxib is combined with 19-norandrostenedione.	Investigational, Withdrawn
Voriconazole	The serum concentration of 19-norandrostenedione can be increased when it is combined with Voriconazole.	Approved, Investigational
Warfarin	19-norandrostenedione may increase the anticoagulant activities of Warfarin.	Approved
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with 19-norandrostenedione.	Approved
Zeranol	The serum concentration of 19-norandrostenedione can be increased when it is combined with Zeranol.	Vet Approved
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with 19-norandrostenedione.	Approved, Investigational, Withdrawn
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with 19-norandrostenedione.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

1. Diel P, Friedel A, Geyer H, Kamber M, Laudenbach-Leschowsky U, Schanzer W, Schleipen B, Thevis M, Vollmer G, Zierau O: The prohormone 19-norandrostenedione displays selective androgen receptor modulator (SARM) like properties after subcutaneous administration. Toxicol Lett. 2008 Apr 1;177(3):198-204. doi: 10.1016/j.toxlet.2008.01.014. Epub 2008 Feb 2. [PubMed:18325697 ]

External Links

KEGG Compound

C14500

PubChem Compound

92834

PubChem Substance

46505377

ChemSpider

83803

ChEBI

34187

PDRhealth

PDRhealth Drug Page

Wikipedia

19-Norandrostenedione

ATC Codes

Not Available

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Clinical Trials

Not Available

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0454 mg/mL	ALOGPS
logP	2.53	ALOGPS
logP	3.63	ChemAxon
logS	-3.8	ALOGPS
pKa (Strongest Acidic)	19.19	ChemAxon
pKa (Strongest Basic)	-4.7	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	34.14 Å2	ChemAxon
Rotatable Bond Count	0	ChemAxon
Refractivity	79.13 m3·mol-1	ChemAxon
Polarizability	31.54 Å3	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9723
Caco-2 permeable	+	0.7785
P-glycoprotein substrate	Substrate	0.5551
P-glycoprotein inhibitor I	Inhibitor	0.8097
P-glycoprotein inhibitor II	Non-inhibitor	0.6972
Renal organic cation transporter	Non-inhibitor	0.638
CYP450 2C9 substrate	Non-substrate	0.827
CYP450 2D6 substrate	Non-substrate	0.9064
CYP450 3A4 substrate	Substrate	0.6816
CYP450 1A2 substrate	Non-inhibitor	0.8259
CYP450 2C9 inhibitor	Non-inhibitor	0.9269
CYP450 2D6 inhibitor	Non-inhibitor	0.94
CYP450 2C19 inhibitor	Non-inhibitor	0.7094
CYP450 3A4 inhibitor	Non-inhibitor	0.8652
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.7931
Ames test	Non AMES toxic	0.9189
Carcinogenicity	Non-carcinogens	0.9403
Biodegradation	Not ready biodegradable	0.9401
Rat acute toxicity	1.6104 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7011
hERG inhibition (predictor II)	Non-inhibitor	0.7574

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
GC-MS Spectrum - EI-B	GC-MS	splash10-00di-2950000000-5865fd40ca280de239b7
Predicted LC-MS/MS Spectrum - 10V, Positive	Predicted LC-MS/MS	Not Available
Predicted LC-MS/MS Spectrum - 20V, Positive	Predicted LC-MS/MS	Not Available
Predicted LC-MS/MS Spectrum - 40V, Positive	Predicted LC-MS/MS	Not Available
Predicted LC-MS/MS Spectrum - 10V, Negative	Predicted LC-MS/MS	Not Available
Predicted LC-MS/MS Spectrum - 20V, Negative	Predicted LC-MS/MS	Not Available
Predicted LC-MS/MS Spectrum - 40V, Negative	Predicted LC-MS/MS	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Lipids and lipid-like molecules

Sub Class

Steroids and steroid derivatives

Direct Parent

Estrogens and derivatives

Alternative Parents

3-oxo delta-4-steroids / 17-oxosteroids / Delta-4-steroids / Cyclohexenones / Organic oxides / Hydrocarbon derivatives

Substituents

Estrogen-skeleton / Oxosteroid / 17-oxosteroid / 3-oxosteroid / 3-oxo-delta-4-steroid / Delta-4-steroid / Cyclohexenone / Cyclic ketone / Ketone / Organic oxygen compound

Molecular Framework

Aliphatic homopolycyclic compounds

External Descriptors

3-oxo steroid (CHEBI:34187 )